SBIR-STTR Award

Evaluating the Usability, Efficacy and Commercial Utility of a Digital Platform to Deliver Comprehensive Treatment for Opioid Use Disorder
Award last edited on: 8/31/2022

Sponsored Program
SBIR
Awarding Agency
NIH : NIDA
Total Award Amount
$1,671,725
Award Phase
2
Solicitation Topic Code
279
Principal Investigator
Jordon D Bosse

Company Information

Boulder Care Inc

223 Bedford Avenue Unit 1167
Brooklyn, NY 11211
   (704) 604-8343
   N/A
   www.boulder.care
Location: Multiple
Congr. District: 12
County: Kings

Phase I

Contract Number: 1R44DA050354-01
Start Date: 9/30/2019    Completed: 8/31/2020
Phase I year
2019
Phase I Amount
$220,921
Opioid use disorder (OUD) is a problem of national concern. Medication-based treatment (MT) reduces opioid use, associated risk behaviors and death. Despite evidence supporting MT with buprenorphine, in more than ½ of US counties (mainly rural), there are no prescribers. Patients travel long distances, join waitlists, or go without MT. Other barriers to care include lack of transportation, competing demands (work, childcare) and stigma. Combined, lack of access and barriers leaves millions without treatment. Our innovative solution (Boulder) is a telehealth-based treatment solution offering long-term support for OUD. Our vision is to deploy care teams (Prescribing Clinician, Nurse Coach, Care Advocate and Certified Peer Coach for each patient) to deliver a comprehensive array of services, supervised by addiction specialists with decades of experience. Technology enables us to effectively scale a program that meets all of NIDA's guidelines for appropriate oversight, and provides low-barrier, patient-centered interventions (e.g. video medication monitoring and private (at home) random observed saliva drug testing. The long-term goal of this proposal is to build a scalable solution able to reach patients who are unable to access evidence-based treatment. Our digital program promises to dramatically improve the patient experience, boosting patient retention, satisfaction, medication adherence, and functional outcomes by providing low barrier, quality care. The patient-facing product is developed. In preliminary testing, patients reported high satisfaction, engagement, and usability, and access to care was increased by 38% in three months. The overall objective is to evaluate the ability of a virtual platform to create the necessary paradigmatic shift in OUD treatment. To achieve this objective, we propose the following aims: Phase I, Aim I: Advance Boulder's mobile platform development and obtain patient feedback; Phase II, Aim II: Determine Boulder's impact on patient engagement, program retention, access to care, and care continuity; and Phase II, Aim III: Determine Boulder's impact on opioid use and patient functional status. Purchasers of our product (e.g. private/commercial/governmental payors, at-risk provider groups, etc.) who provide remuneration on a per-patient, per-month basis, realizing substantial cost savings through our integrated services. Unlike typical fee-for-service care delivery, our economic model aligns incentives around delivering superior patient outcomes. The virtual OUD treatment product's end-users are resource-constrained patients who will access care no cost to them. Technology enables our team of medical, behavioral, and social service providers to bring comprehensive telehealth-based care for the longitudinal management of addictive disease directly to the patient, rather than bringing the patient to the care. The research team includes staff and affiliates of Boulder, the Addiction Research and Education Foundation and community partners. Boulder's current investors provide a wide range of support services to ensure success through a national network of experienced entrepreneurs and leaders that provide mentorship and guidance.

Public Health Relevance Statement:
8. PROJECT NARRATIVE It is very difficult to find quality care for opioid use disorder. Most programs have a lot of requirements that make it hard to start treatment and stay with it. Boulder's app brings your team of doctors and coaches right to you. Our program will help people will stay in treatment longer, be happier, and have a better quality of life.

NIH Spending Category:
Behavioral and Social Science; Brain Disorders; Clinical Research; Drug Abuse (NIDA only); Health Services; Opioid Misuse and Addiction; Opioids; Rural Health; Substance Abuse

Project Terms:
addiction; Advocate; Ambulatory Care; barrier to care; base; Behavioral; Buprenorphine; care delivery; Caring; Cessation of life; commercial application; Communication; Communities; Complex; Continuity of Patient Care; cost; Cost Savings; County; Development; digital; Disease; drug testing; Economic Models; Education; Emergency Department patient; Employment Status; Ensure; Epidemic; Evidence based treatment; experience; Fee-for-Service Plans; Feedback; Foundations; functional outcomes; functional status; Goals; Government; Guidelines; Health Services Accessibility; Home environment; Housing; improved; Incentives; individualized medicine; innovation; Intervention; Life; Long-Term Care; Medical; medication compliance; Mentorship; mobile application; mobile computing; Monitor; National Institute of Drug Abuse; Nature; Nurses; opioid epidemic; opioid use; opioid use disorder; Outcome; patient engagement; patient oriented; Patient-Focused Outcomes; Patients; peer coaching; Pharmaceutical Preparations; Phase; Privatization; programs; Provider; Psychiatric Social Work; Quality of Care; Quality of life; recruit; Remunerations; Reporting; Research; Resources; Risk; Risk Behaviors; Rural; rural area; Saliva; satisfaction; Savings; Schedule; service providers; Services; social stigma; Social Work; Source; Specialist; success; Supervision; Technology; telehealth; Testing; Text; Time; traditional care; Transportation; Travel; treatment planning; usability; virtual; Vision; Visit; Waiting Lists; Work

Phase II

Contract Number: 4R44DA050354-02
Start Date: 9/30/2019    Completed: 3/31/2023
Phase II year
2021
(last award dollars: 2022)
Phase II Amount
$1,450,804

7. Opioid use disorder (OUD) is a problem of national concern. Medication-based treatment (MT) reduces opioiduse, associated risk behaviors and death. Despite evidence supporting MT with buprenorphine, in more than ½of US counties (mainly rural), there are no prescribers. Patients travel long distances, join waitlists, or gowithout MT. Other barriers to care include lack of transportation, competing demands (work, childcare) andstigma. Combined, lack of access and barriers leaves millions without treatment. Our innovative solution(Boulder) is a telehealth-based treatment solution offering long-term support for OUD. Our vision is to deploycare teams (Prescribing Clinician, Nurse Coach, Care Advocate and Certified Peer Coach for each patient) todeliver a comprehensive array of services, supervised by addiction specialists with decades of experience.Technology enables us to effectively scale a program that meets all of NIDA's guidelines for appropriateoversight, and provides low-barrier, patient-centered interventions (e.g. video medication monitoring andprivate (at home) random observed saliva drug testing. The long-term goal of this proposal is to build ascalable solution able to reach patients who are unable to access evidence-based treatment. Our digitalprogram promises to dramatically improve the patient experience, boosting patient retention, satisfaction,medication adherence, and functional outcomes by providing low barrier, quality care. The patient-facingproduct is developed. In preliminary testing, patients reported high satisfaction, engagement, and usability, andaccess to care was increased by 38% in three months. The overall objective is to evaluate the ability of avirtual platform to create the necessary paradigmatic shift in OUD treatment. To achieve this objective, wepropose the following aims: Phase I, Aim I: Advance Boulder's mobile platform development and obtainpatient feedback; Phase II, Aim II: Determine Boulder's impact on patient engagement, program retention,access to care, and care continuity; and Phase II, Aim III: Determine Boulder's impact on opioid use andpatient functional status. Purchasers of our product (e.g. private/commercial/governmental payors, at-riskprovider groups, etc.) who provide remuneration on a per-patient, per-month basis, realizing substantial costsavings through our integrated services. Unlike typical fee-for-service care delivery, our economic model alignsincentives around delivering superior patient outcomes. The virtual OUD treatment product's end-users areresource-constrained patients who will access care no cost to them. Technology enables our team of medical,behavioral, and social service providers to bring comprehensive telehealth-based care for the longitudinalmanagement of addictive disease directly to the patient, rather than bringing the patient to the care. Theresearch team includes staff and affiliates of Boulder, the Addiction Research and Education Foundation andcommunity partners. Boulder's current investors provide a wide range of support services to ensure successthrough a national network of experienced entrepreneurs and leaders that provide mentorship and guidance.

Public Health Relevance Statement:
8. PROJECT NARRATIVE It is very difficult to find quality care for opioid use disorder. Most programs have a lot of requirements that make it hard to start treatment and stay with it. Boulder's app brings your team of doctors and coaches right to you. Our program will help people will stay in treatment longer, be happier, and have a better quality of life.

Project Terms: